Hyaluronic acid in end-stage renal disease treated by hemodialysis

Orășan, Olga Hilda; Orășan, Remus; Paţiu, Ioan Mihai; Dumitraşcu, Dan L.

doi:10.3109/0886022x.2015.1077312

Cited by 6 publications

(6 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum HA is a biomarker that has been proven useful in distinguishing between various fibrosis stages. In a previous study, we detected cut-off values for hyaluronic acid that can differentiate between F0/1 (33.46 ng/ml), F1/2 (80.24 ng/ml) and F2/3 (88.54 ng/ml), but none of the F stages determined by HA could be associated with a risk for TCP in our patients (11,29).…”

Section: Discussionmentioning

confidence: 56%

Thrombocytopenia in end-stage renal disease and chronic viral hepatitis B or C

Orășan¹,

Urian²,

Ciulei³

et al. 2018

JMMS

View full text Add to dashboard Cite

Objectives. We evaluated platelet counts in end-stage renal disease and chronic viral hepatitis. Materials and Methods. We studied 70 patients with end-stage renal disease and chronic viral hepatitis and compared them to a control group of 45 patients without hepatitis. Results. The presence of viral hepatitis was associated with a higher prevalence of thrombocytopenia. Correlations between age, C-reactive protein, liver stiffness measurement, and platelet count were observed. C-reactive protein levels > 10 mg/dl were associated with a lower risk of thrombocytopenia in patients with end-stage renal disease and chronic viral hepatitis, yet age > 60 years, dialysis vintage > 10 years, aspartate and alanine aminotransferase levels > 20 IU/L, albumin levels < 3.5 g/dl, and fibrosis stage ≥ 3 were not related. Conclusions. Chronic viral hepatitis leads to a higher prevalence of thrombocytopenia. Platelet counts in these patients begin to decrease significantly once liver fibrosis reaches stage III. Keywords  thrombocytopenia, end-stage renal disease, chronic viral hepatitis Highlights ✓ Thrombocytopenia is a common occurrence in patients with end-stage renal disease undergoing hemodialysis; ✓ Chronic viral hepatitis B or C in end-stage renal disease patients does not impact platelet counts, suggesting that the natural course of liver disease is slowed in subjects undergoing hemodialysis

show abstract

Section: Discussionmentioning

confidence: 56%

Thrombocytopenia in end-stage renal disease and chronic viral hepatitis B or C

Orășan¹,

Urian²,

Ciulei³

et al. 2018

JMMS

View full text Add to dashboard Cite

show abstract

“…Patients with higher chance to maintain Hb levels above 12 g/dL without ESA were men, of a lower age and with a higher dialysis vintage (8,9). The use of a percutaneous HD catheter was associated with a lower likelihood of being part of the non-ESA group.…”

Section: Discussionmentioning

confidence: 97%

Effect of long period treatment with erythropoiesis stimulating agents on clinically and laboratory parameters in hemodialysis autosomal dominant polycystic kidney disease patients

Orășan

Petrov

Urian

et al. 2017

Revista Romana De Medicina De Laborator

Self Cite

View full text Add to dashboard Cite

show abstract

“…None of the mentioned tests could determine the F4 score. Hyaluronic acid has the highest clinical utility for stage F1 (clinical net benefit 0Á22%) and F2 (clinical net benefit 0Á18%), but its efficiency to differentiate chronic hepatitis from liver cirrhosis was not demonstrated [55][56][57].…”

Section: Detection Of Central Venous Catheter-related Bloodstream Infmentioning

confidence: 99%